Tags

Type your tag names separated by a space and hit enter

Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study.
Neurol Sci. 2020 Jul; 41(7):1647-1650.NS

Abstract

We assessed the prevalence and impact of COVID-19 among multiple sclerosis (MS) patients across Europe by leveraging participant data collected as part of the ongoing EU IMI2 RADAR-CNS major programme aimed at finding new ways of monitoring neurological disorders using wearable devices and smartphone technology. In the present study, 399 patients of RADAR-MS have been included (mean age 43.9 years, 60.7% females) with 87/399 patients (21.8%) reporting major symptoms suggestive of COVID-19. A trend for an increased risk of COVID-19 symptoms under alemtuzumab and cladribine treatments in comparison to injectables was observed. Remote monitoring technologies may support health authorities in monitoring and containing the ongoing pandemic.

Authors+Show Affiliations

Institute of Experimental Neurology, IRCCS Ospedale San Raffaele, via Olgettina 60, 20132, Milan, Italy. Neurorehabilitation Unit, IRCCS Ospedale San Raffaele, Milan, Italy.Institute of Experimental Neurology, IRCCS Ospedale San Raffaele, via Olgettina 60, 20132, Milan, Italy. Neurorehabilitation Unit, IRCCS Ospedale San Raffaele, Milan, Italy.Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.The Department of Biostatistics and Health informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Institute of Health Informatics, University College London, London, UK.Embedded Intelligence for Health Care & Wellbeing, University of Augsburg, Augsburg, Germany.Janssen Research and Development, LLC, Titusville, NJ, USA.The Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.Institute of Experimental Neurology, IRCCS Ospedale San Raffaele, via Olgettina 60, 20132, Milan, Italy. comi.giancarlo@hsr.it.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32617741

Citation

Dalla Costa, Gloria, et al. "Real-time Assessment of COVID-19 Prevalence Among Multiple Sclerosis Patients: a Multicenter European Study." Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, vol. 41, no. 7, 2020, pp. 1647-1650.
Dalla Costa G, Leocani L, Montalban X, et al. Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. Neurol Sci. 2020;41(7):1647-1650.
Dalla Costa, G., Leocani, L., Montalban, X., Guerrero, A. I., Sørensen, P. S., Magyari, M., Dobson, R. J. B., Cummins, N., Narayan, V. A., Hotopf, M., & Comi, G. (2020). Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 41(7), 1647-1650. https://doi.org/10.1007/s10072-020-04519-x
Dalla Costa G, et al. Real-time Assessment of COVID-19 Prevalence Among Multiple Sclerosis Patients: a Multicenter European Study. Neurol Sci. 2020;41(7):1647-1650. PubMed PMID: 32617741.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. AU - Dalla Costa,Gloria, AU - Leocani,Letizia, AU - Montalban,Xavier, AU - Guerrero,Ana Isabel, AU - Sørensen,Per Soelberg, AU - Magyari,Melinda, AU - Dobson,Richard J B, AU - Cummins,Nicholas, AU - Narayan,Vaibhav A, AU - Hotopf,Matthew, AU - Comi,Giancarlo, AU - ,, Y1 - 2020/07/02/ PY - 2020/06/03/received PY - 2020/06/16/accepted PY - 2020/7/4/pubmed PY - 2020/7/28/medline PY - 2020/7/4/entrez KW - COVID-19 KW - Multiple Sclerosis KW - Remote monitoring technologies SP - 1647 EP - 1650 JF - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology JO - Neurol. Sci. VL - 41 IS - 7 N2 - We assessed the prevalence and impact of COVID-19 among multiple sclerosis (MS) patients across Europe by leveraging participant data collected as part of the ongoing EU IMI2 RADAR-CNS major programme aimed at finding new ways of monitoring neurological disorders using wearable devices and smartphone technology. In the present study, 399 patients of RADAR-MS have been included (mean age 43.9 years, 60.7% females) with 87/399 patients (21.8%) reporting major symptoms suggestive of COVID-19. A trend for an increased risk of COVID-19 symptoms under alemtuzumab and cladribine treatments in comparison to injectables was observed. Remote monitoring technologies may support health authorities in monitoring and containing the ongoing pandemic. SN - 1590-3478 UR - https://www.unboundmedicine.com/medline/citation/32617741/Real-time_assessment_of_COVID-19_prevalence_among_multiple_sclerosis_patients:_a_multicenter_European_study L2 - https://link.springer.com/10.1007/s10072-020-04519-x DB - PRIME DP - Unbound Medicine ER -